Meso‐Hannokinol inhibits breast cancer bone metastasis via the ROS/JNK/ZEB1 axis

Abstract

AbstractDistal metastases from breast cancer, especially bone metastases, are extremely common in the late stages of the disease and are associated with a poor prognosis. EMT is a biomarker of the early process of bone metastasis, and MMP‐9 and MMP‐13 are important osteoclastic activators. Previously, we found that meso‐Hannokinol (HA) could significantly inhibit EMT and MMP‐9 and MMP‐13 expressions in breast cancer cells. On this basis, we further explored the role of HA in breast cancer bone metastasis. In vivo, we established a breast cancer bone metastasis model by intracardially injecting breast cancer cells. Intraperitoneal injections of HA significantly reduced breast cancer cell metastasis to the leg bone in mice and osteolytic lesions caused by breast cancer. In vitro, HA inhibited the migration and invasion of breast cancer cells and suppressed the expressions of EMT, MMP‐9, MMP‐13, and other osteoclastic activators. HA inhibited EMT and MMP‐9 by activating the ROS/JNK pathway as demonstrated by siJNK and SP600125 inhibition of JNK phosphorylation and NAC scavenging of ROS accumulation. Moreover, HA promoted bone formation and inhibited bone resorption in vitro. In conclusion, our findings suggest that HA may be an excellent candidate for treating breast cancer bone metastasis.